pyrazines has been researched along with abt-737 in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (46.15) | 29.6817 |
2010's | 7 (53.85) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Anderson, KC; Brahmandam, M; Chauhan, D; Ghobrial, I; Hideshima, T; Munshi, N; Podar, K; Raje, N; Richardson, P; Schlossman, R; Velankar, M | 1 |
Andreeff, M; Ashihara, E; Kamitsuji, Y; Kawata, E; Kimura, S; Kuroda, J; Maekawa, T; O'Reilly, LA; Strasser, A; Tabe, Y; Takeuchi, M; Tanaka, R; Taniwaki, M; Yokota, A | 1 |
Bhagat, G; Furman, RR; Gardner, JR; Gonen, M; Gueorguiev, VD; Heaney, ML; Manova, K; O'Connor, OA; Paoluzzi, L; Scotto, L | 1 |
Barbone, D; Broaddus, VC; Fennell, DA; Yang, TM | 1 |
Grandis, JR; Johnson, DE; Li, C; Li, R; Patel, NS; Zang, Y | 1 |
Kagechika, H; Kurosu, T; Miura, O; Ohki, M; Wu, N | 1 |
Gartel, AL; Pandit, B | 1 |
Al Sabah, S; Armstrong, JL; Corazzari, M; Ellis, N; Falasca, L; Fimia, GM; Hill, DS; Lovat, PE; Martin, S; Pagliarini, V; Piacentini, M; Redfern, CP | 1 |
Bollard, CM; Buglio, D; Derenzini, E; Illés, A; Ji, Y; Jóna, A; Khaskhely, N; Medeiros, LJ; Shafer, JA; Younes, A | 1 |
Agostino, NR; DiDomenico, JD; Jane, EP; Pollack, IF; Premkumar, DR; Vukmer, NA | 1 |
Borst, J; Rooswinkel, RW; van de Kooij, B; Verheij, M | 1 |
Geltink, RI; Grosveld, GC; Marshall, AD; Picchione, F | 1 |
Ishitsuka, K; Katsuya, H; Kunami, N; Nogami, R; Tamura, K | 1 |
13 other study(ies) available for pyrazines and abt-737
Article | Year |
---|---|
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; Biphenyl Compounds; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Division; Cell Survival; Humans; Multiple Myeloma; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Tumor Cells, Cultured | 2007 |
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcr; Pyrazines; Pyrimidines; Sulfonamides | 2007 |
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Health; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mice; Microscopy, Confocal; Molecular Mimicry; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Tissue Donors; Xenograft Model Antitumor Assays | 2008 |
Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Communication; Cell Line, Tumor; Diffusion; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Nitrophenols; Phosphatidylinositol 3-Kinases; Piperazines; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recombinant Proteins; Signal Transduction; Spheroids, Cellular; Sulfonamides; Time Factors; TNF-Related Apoptosis-Inducing Ligand; TOR Serine-Threonine Kinases | 2009 |
ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Biphenyl Compounds; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Synergism; Head and Neck Neoplasms; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Sulfonamides | 2009 |
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Benzopyrans; Biphenyl Compounds; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Mutation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2009 |
New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Humans; Male; Nitrophenols; Nucleosides; Peptides; Piperazines; Prostate; Pyrazines; Pyrimidines; Sulfonamides; Thiostrepton | 2010 |
Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biphenyl Compounds; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum; Female; Fenretinide; Humans; Luminescent Proteins; Melanoma; Mice; Microscopy, Fluorescence; Microtubule-Associated Proteins; Nitrophenols; Piperazines; Proto-Oncogene Proteins B-raf; Pyrazines; RNA Interference; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hodgkin Disease; Humans; Indoles; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Processing, Post-Translational; Pyrazines; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2011 |
ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Topics: Annexins; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Biphenyl Compounds; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Glioma; Humans; Mitochondrial Diseases; NF-kappa B; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-akt; Pyrazines; Sulfonamides | 2012 |
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; T-Lymphocytes; Tumor Suppressor Protein p53 | 2012 |
PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis.
Topics: Animals; Apoptosis; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Mice; Myoblasts; Nitrophenols; Oligopeptides; Oncogene Proteins, Fusion; Paired Box Transcription Factors; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rhabdomyosarcoma, Alveolar; Sulfonamides; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia-Lymphoma, Adult T-Cell; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Vorinostat | 2014 |